MMP-9 responsive hydrogel promotes diabetic wound healing by suppressing ferroptosis of endothelial cells

Ferroptosis plays a crucial role in the progression of diabetic wounds, suggesting potential therapeutic strategies to target ferroptosis. Transient receptor potential ankyrin 1 (TRPA1) is a non-selective calcium channel that acts as a receptor for a variety of physical or chemical stimuli. Cinnamaldehyde (CA) is a specific TRPA1 agonist. In in vitro experiments, we observed that high glucose (HG) treatment induced endothelial cell ferroptosis, impairing cell function. CA successfully inhibited endothelial cell ferroptosis, improving migration, proliferation, and tube formation. Further mechanistic studies showed that CA-activated TRPA1-induced Ca 2+ influx promoted the phosphorylation of calmodulin-dependent protein kinase II (CaMKII) and nuclear factor-E 2-related factor 2 (Nrf2) translocation, which contributed to the elevation of glutathione peroxidase 4 (GPX4), leading to the inhibition of endothelial cell ferroptosis. In addition, CA was incorporated into an MMP-9-responsive injectable duplex hybrid hydrogel (CA@HA-Gel), allowing its efficient sustained release into diabetic wounds in an inflammation-responsive manner. The results showed that CA@HA-Gel inhibited wound endothelial cell ferroptosis and significantly promoted diabetic wound healing. In summary, the results presented in this study emphasize the potential therapeutic application of CA@HA-Gel in the treatment of diseases associated with ferroptosis. Scheme 1. Schematic illustration of therapeutic process for diabetic wound healing by using CA-loaded hydrogel. • Ferroptosis was found in the diabetic wound. • TRPA1 inhibits endothelial cell ferroptosis through the Ca 2+ /CaMKII/Nrf2/GPX4 signaling pathway. • MMP-9 responsive injectable duplex hybrid hydrogel can respond to inflammation with sustained Cinnamaldehyde release. • CA@HA-Gel promotes diabetic wound healing by regulating endothelial cell proliferation, migration, and tube formation.